Perceived awareness of and readiness to receive various COVID-19 vaccine candidates by healthcare workers
| Vaccine candidate | No (%) knows about vaccine* | No (%) willingness to take the vaccine | ||
| Never | Maybe | Sure | ||
| AstraZeneca (Oxford University: British/Swedish) non-replicating viral vector (chimpanzee adenovirus vectored vaccine (ChAdOx1 nCoV-19) | 594 (39.3) | 159 (10.5) | 984 (65.1) | 369 (24.4) |
| Gamaleya (Russia)-Sputnik V non-replicating viral vector adenovirus (Gam-COVID-Vac) | 482 (31.9) | 271 (17.9) | 1100 (72.8) | 141 (9.3) |
| Pfizer RNA (BNT162b2; USA): nucleoside-modified messenger RNA (modRNA) | 466 (30.8) | 154 (10.2) | 1042 (68.9) | 316 (20.9) |
| Johnson and Johnson (USA; adenovirus type 26 vector; Ad26.COV2-S) | 422 (27.9) | 154 (10.2) | 1108 (73.3) | 250 (16.5) |
| CanSino (China; adenovirus type 5; Ad5-vectored) | 397 (26.3) | 277 (18.3) | 1103 (72.3) | 132 (8.7) |
| Novavax (USA) protein subunit (full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M; NVX-CoV2373) | 364 (24.1) | 166 (11) | 1139 (75.3) | 208 (13.8) |
| Moderna RNA (USA; mRNA-1273) | 301 (19.9) | 170 (11.2) | 1142 (75.5) | 200 (13.2) |
*Percentage expressed of total sample (N=1512 healthcare workers).